Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Sulisobenzone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.51 |
| ▸ | PDE4D known ✓ | Q08499 | 1/20 | 0.51 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.41 |
| ▸ | NOD2 known ✓ | Q9HC29 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 5/20 | 0.76 |
| ▸ | MAPT | P10636 | 5/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.76 |
| ▸ | HPGD | P15428 | 3/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | RECQL | P46063 | 1/20 | 0.66 |
| ▸ | HTT | P42858 | 3/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | PGR | P06401 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulisobenzone SCHEMBL338882 | 1.00 | LMNA (0.76) | LMNAMAPTKMT2AALDH1A1HPGD | |
| Sulisobenzone SCHEMBL28588923 | 0.99 | LMNA (0.74) | LMNAMAPTKMT2AALDH1A1HPGD | |
| Sulisobenzone SCHEMBL11277588 | 0.97 | LMNA (0.76) | LMNAMAPTKMT2AALDH1A1HPGD | |
| Sulisobenzone SCHEMBL6295947 | 0.97 | LMNA (0.76) | LMNAMAPTKMT2AALDH1A1HPGD | |
| Sulisobenzone SCHEMBL10621756 | 0.97 | LMNA (0.76) | LMNAMAPTKMT2AALDH1A1HPGD | |
| Sulisobenzone SCHEMBL10491696 | 0.97 | LMNA (0.76) | LMNAMAPTKMT2AALDH1A1HPGD | |
| Sulisobenzone SCHEMBL10723288 | 0.97 | LMNA (0.76) | LMNAMAPTKMT2AALDH1A1HPGD | |
| Sulisobenzone SCHEMBL2209368 | 0.94 | LMNA (0.71) | LMNAMAPTKMT2AALDH1A1HPGD | |
| Sulisobenzone SCHEMBL5147287 | 0.90 | LMNA (0.65) | LMNAMAPTKMT2AALDH1A1HPGD | |
| SCHEMBL240880 | 0.87 | LMNA (0.56) | LMNAMAPTKMT2AALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3600224-B1 | SKIN CARE COMPOSITIONS COMPRISING A TERPOLYMER, PROCESS FOR PREPARING THE SAME AND METHOD OF USE THEREOF | ISP INVESTMENTS LLC (US) | 2026-05-06 | — | — | EP | claimed |
| EP-4518849-B1 | COMPOSITION FOR TOPICAL APPLICATION FOR THE PHOTOTHERAPEUTIC TREATMENT OF INFLAMMATORY-BASED SKIN DISEASES | GIULIANI SPA (IT) | 2026-04-08 | — | — | EP | claimed |
| EP-3709966-B1 | COMPOSITIONS COMPRISING AT LEAST ONE ACRYLIC POLYMER AND AT LEAST ONE INSOLUBLE ORGANIC SCREENING AGENT | OREAL (FR) | 2024-12-11 | — | — | EP | claimed |
| WO-2024027193-A1 | SKIN-CARE PRODUCT COMPOSITION AND PHARMACEUTICAL COMPOSITION COMPRISING SULFONATED CALIXARENE, AND USE OF SULFONATED CALIXARENE | 苏州隽德生物科技有限公司 | 2024-02-08 | — | — | WO | claimed |
| CN-113754932-B | Photo-aging-resistant latex product and manufacturing method thereof | 温州卡美琳乳胶制品有限公司 | 2023-03-03 | — | — | CN | claimed |
| CN-115003388-A | Aqueous sunscreen formulations based on sulfated crystalline cellulose SPF boosters | 陶氏环球技术有限责任公司 | 2022-09-02 | — | — | CN | claimed |
| EP-3773444-B1 | COSMETIC COMPOSITION FOR A FAST SWEAT EVAPORATION | BEIERSDORF AG (DE) | 2022-03-02 | — | — | EP | claimed |
| CN-108671267-B | Absorbent and reflective biocompatible dyes for high precision medical implants | H·戴维·迪恩 | 2022-02-18 | — | — | CN | claimed |
| EP-3946642-A1 | SUNSCREEN COMPOSITIONS AND METHOD OF USE THEREOF | ISP Investments LLC (US) | 2022-02-09 | — | — | EP | claimed |
| EP-3600224-B1 | SKIN CARE COMPOSITIONS COMPRISING A TERPOLYMER, PROCESS FOR PREPARING THE SAME AND METHOD OF USE THEREOF | ISP INVESTMENTS LLC (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4104010-B1 | A FUNCTIONAL AND TRANSPARENT GEL ELECTROLYTE SYSTEM AND FAST SWITCHING ELECTROCHROMIC/ELECTROCHEMICAL DEVICES THEREOF | COUNCIL OF SCIENT AND INDUSTRIAL RESEARCH AN INDIAN REGISTERED BODY INCORPORATED UNDER REGN OF SOC A (IN) | 2026-05-06 | — | — | EP | disclosed |
| EP-3389618-B2 | PROCESS FOR TREATING KERATIN FIBRES USING AN AQUEOUS COMPOSITION COMPRISING A COMBINATION OF PARTICULAR ALKOXYSILANES | OREAL (FR) | 2026-04-22 | — | — | EP | disclosed |
| WO-2026044006-A1 | MODIFIED STARCH COMPOUNDS AND USES THEREOF | ISP INVESTMENTS LLC (US) | 2026-02-26 | — | — | WO | disclosed |
| EP-4698227-A1 | SUPRAMOLECULAR ASSEMBLIES, COMPOSITIONS COMPRISING THE SAME AND METHODS FOR PRODUCING THE SAME | ELC Management LLC (US) | 2026-02-25 | — | — | EP | disclosed |
| CN-110785452-B | Process for preparing organopolysiloxane gels | 瓦克化学股份公司 | 2022-05-13 | — | — | CN | disclosed |
| US-20220144785-A1 | COMPOUNDS HAVING EXCITED STATE INTRAMOLECULAR PROTON TRANSFER (ESIPT) CHARACTER FOR USE IN TREATING AND/OR PREVENTING SUNBURN AND/OR PREVENTING U.V. DAMAGE | UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG (ZA) | 2022-05-12 | — | — | US | disclosed |
| WO-2022063405-A1 | METHOD FOR PRODUCING HYDROPHILIC ORGANOPOLYSILOXANE GELS | WACKER CHEMIE AG (DE) | 2022-03-31 | — | — | WO | disclosed |
| CN-109475482-B | Medicine | 西姆莱斯股份公司 | 2022-03-29 | — | — | CN | disclosed |
| CN-114206426-A | Device and method for applying a cosmetic composition by means of a grated end-effector | 强生消费者公司 | 2022-03-18 | — | — | CN | disclosed |
| CN-108671267-B | Absorbent and reflective biocompatible dyes for high precision medical implants | H·戴维·迪恩 | 2022-02-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144785-A1 | COMPOUNDS HAVING EXCITED STATE INTRAMOLECULAR PROTON TRANSFER (ESIPT) CHARACTER FOR USE IN TREATING AND/OR PREVENTING SUNBURN AND/OR PREVENTING U.V. DAMAGE | NNT, NQO1, SUN2 | PDE4A 4862/4885PDE4D 4815/4885PTGS1 1801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.